98%
921
2 minutes
20
We aimed to determine the mental health and cognitive outcomes at six months in people who had not been hospitalized with COVID-19 and who had tested positive or negative for COVID-19 in Eastern Ontario, Canada. Participants were matched 1:1 six months following their COVID-19 polymerase chain reaction test. X2, -test, and Mann-Whitney U tests were conducted to compare self-report and observer-rated mental health and cognitive outcomes between the two groups. We also conducted an age and gender-adjusted logistic regression analysis to explore risk factors associated with depression, anxiety, and cognitive impairment among those who had tested positive for COVID-19. A total of 324 participants were enrolled ( = 162 per arm). Overall, 40.7% of those in the COVID-positive group were men, with an average age of 37.9 (SD 13.2) years. In the COVID-negative group, 41.4% were men, with an average age of 36.7 (SD 12.8). There were no statistically significant differences in mental health outcomes between the groups. On cognitive testing, while 21% of the COVID-positive participants and 14% of the COVID-negative participants had scores indicating significant cognitive impairment, the difference between groups was not significant, though this warrants further investigation in future research. In non-hospitalized patients who have tested positive for COVID-19, there is no evidence of an increase in mental health disorders compared to people who tested negative. Any increases in mental health disorders during the pandemic may be the effect of social changes rather than an effect of the virus itself. The exception may be the cognitive changes in those who tested positive.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12386409 | PMC |
http://dx.doi.org/10.3390/ijerph22081249 | DOI Listing |
J Med Internet Res
September 2025
Department of Psychiatry, Helsinki University Hospital and Helsinki University, Helsinki, Finland.
Background: Internet-based cognitive behavioral therapies (iCBTs) are typically categorized into 2 types: therapist-assisted and self-guided. Both formats have accumulated substantial evidence supporting their cost-effectiveness and efficacy in treating a range of mental health conditions. However, therapist-assisted iCBTs tend to show lower dropout rates than self-guided versions.
View Article and Find Full Text PDFJMIR Ment Health
September 2025
National Institute of Health and Care Research MindTech HealthTech Research Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Background: Cross-sector collaboration is increasingly recognized as essential for addressing complex health challenges, including those in mental health. Industry-academic partnerships play a vital role in advancing research and developing health solutions, yet differing priorities and perspectives can make collaboration complex.
Objective: This study aimed to identify key principles to support effective industry-academic partnerships, from the perspective of industry partners, and develop this into actionable guidance, which can be applied across sectors.
JMIR Res Protoc
September 2025
National Institute of Public Health, University of Southern Denmark, Copenhagen K, Denmark.
Background: The high and increasing rate of poor mental health among young people is a matter of global concern. Experiencing poor mental health during this formative stage of life can adversely impact interpersonal relationships, academic and professional performance, and future health and well-being if not addressed early. However, only a few of those in need seek help.
View Article and Find Full Text PDFNeuro Endocrinol Lett
September 2025
Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Background: Major depressive disorder (MDD) is associated with neuro-immune - metabolic - oxidative (NIMETOX) pathways.
Aims: To examine the connections among NIMETOX pathways in outpatient MDD (OMDD) with and without metabolic syndrome (MetS); and to determine the prevalence of NIMETOX aberrations in a cohort of OMDD patients.
Methods: We included 67 healthy controls and 66 OMDD patients and we assessed various NIMETOX pathways.